Summit Therapeutics

SMMT · Nasdaq · United States

Share price · SMMT

$10.50-2.32 (-18.10%) 3M

close as of 2026-11-18 · 24h delayed · vol 12.1M (2.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when SMMT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 16 Nov 2026-16.5%
  2. 6 Nov 2026+15.1%
  3. 3 Sep 2026+17.3%
  4. 26 Aug 2026+6.5%
  5. 1 May 2026-24.9%
  6. 22 Apr 2026-6.8%
  7. 16 Apr 2026+15.6%

    Nothing announced by SMMT that day or the session before.

  8. 25 Mar 2026+15.4%
  9. 20 Jan 2026-5.8%
  10. 12 Jan 2026-13.4%

Share of unusual movement by asset

For each asset, the share of SMMT's own-move activity since 30 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Ivonescimab
events and moves
1614%
Other company news (earnings, financing, releases naming no asset)—33%
Sessions with no dated event—53%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
PD-1 + VEGFAMultispecific antibody
Non-Small Cell Lung CancerBiliary Tract CancerColorectal Cancer
Metastatic Colorectal Cancer

Upcoming events

(27 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (5)
December 2026 (5)
IvonescimabPhase 1/2Solid Tumor, Adult
Est. primary completion 2026-12 · NCT05689853 · CT.gov ↗
What to watch
IvonescimabPhase 3Triple-Negative Breast Cancer (TNBC)
Est. primary completion 2026-12 · NCT06767527 · CT.gov ↗
What to watch
IvonescimabPhase 1/2Metastatic Pancreatic Ductal Adenocarcinoma
Est. primary completion 2026-12-30 · NCT06646055 · CT.gov ↗
What to watch
IvonescimabPhase 2Metastatic Triple-negative Breast Cancer, Locally Advanced Triple-negative Breast Cancer
Est. primary completion 2026-12-30 · NCT05227664 · CT.gov ↗
What to watch
IvonescimabPhase 1/2Advanced Malignant Tumors
Est. primary completion 2026-12-31 · NCT05229497 · CT.gov ↗
What to watch
2027 (12)
January 2027 (2)
IvonescimabPhase 3Head and Neck Squamous Cell Carcinoma
Est. primary completion 2027-01 · NCT06601335 · CT.gov ↗
What to watch
IvonescimabPhase 3Colorectal Adenocarcinoma
Est. primary completion 2027-01-13 · NCT06951503 · CT.gov ↗
What to watch
February 2027 (1)
IvonescimabPhase 1/2Colorectal Cancer With Hepatic Metastases
Est. primary completion 2027-02-28 · NCT07357220 · CT.gov ↗
What to watch
May 2027 (4)
IvonescimabPhase 1/2Biliary Tract Cancer
Est. primary completion 2027-05 · NCT06938321 · CT.gov ↗
What to watch
IvonescimabPhase 3Non-Small Cell Lung Cancer
Est. primary completion 2027-05 · NCT06928389 · CT.gov ↗
What to watch
IvonescimabPhase 2Hepatocellular Carcinoma (HCC)
Est. primary completion 2027-05-10 · NCT07052253 · CT.gov ↗
What to watch
IvonescimabPhase 3Pancreatic Cancer
Est. primary completion 2027-05-14 · NCT06953999 · CT.gov ↗
What to watch
August 2027 (2)
IvonescimabPhase 2Pancreatic Cancer
Est. primary completion 2027-08 · NCT07114315 · CT.gov ↗
What to watch
IvonescimabPhase 2Advanced Non Small Cell Lung Cancer (NSCLC)
Est. primary completion 2027-08-30 · NCT07669779 · CT.gov ↗
What to watch
September 2027 (1)
IvonescimabPhase 2Advanced Breast Cancer
Est. primary completion 2027-09-01 · NCT07591090 · CT.gov ↗
What to watch
October 2027 (1)
IvonescimabPhase 2Platinum-sensitive Ovarian Cancer
Est. primary completion 2027-10 · NCT06686030 · CT.gov ↗
What to watch
December 2027 (1)
IvonescimabPhase 2Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Est. primary completion 2027-12 · NCT07245446 · CT.gov ↗
What to watch
2028 (8)
April 2028 (1)
IvonescimabPhase 3Non-Small Cell Lung Cancer
Est. primary completion 2028-04 · NCT06767514 · CT.gov ↗
What to watch
May 2028 (1)
IvonescimabPhase 3Metastatic Colorectal Cancer (CRC)
Est. primary completion 2028-05-31 · NCT07228832 · CT.gov ↗
What to watch
June 2028 (2)
IvonescimabPhase 1/2Breast Cancer
Est. primary completion 2028-06-06 · NCT07560124 · CT.gov ↗
What to watch
IvonescimabPhase 1/2Non-Small Cell Lung Cancer
Est. primary completion 2028-06-18 · NCT07623356 · CT.gov ↗
What to watch
August 2028 (1)
IvonescimabPhase 2Urothelial Carcinoma (UC)
Est. primary completion 2028-08-24 · NCT07636772 · CT.gov ↗
What to watch
September 2028 (1)
IvonescimabPhase 2Non-Small Cell Lung Cancer
Est. primary completion 2028-09 · NCT07158840 · CT.gov ↗
What to watch
December 2028 (2)
IvonescimabPhase 3Non-Small Cell Lung Cancer
Est. primary completion 2028-12-31 · NCT05899608 · CT.gov ↗
What to watch
IvonescimabPhase 3Small Cell Lung Cancer
Est. primary completion 2028-12-31 · NCT07010263 · CT.gov ↗
What to watch
2029 (1)
April 2029 (1)
IvonescimabPhase 2Renal Cell Carcinoma, Clear Cell
Est. primary completion 2029-04-12 · NCT07877194 · CT.gov ↗
What to watch
2030 (1)
October 2030 (1)
IvonescimabPhase 2/3Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma (UC)
Est. primary completion 2030-10-31 · NCT07815665 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

14 November 2026FDA action dateIvonescimabIvonescimab PDUFA goal action date (EGFRm NSCLC post-TKI)
US, FDA · FDA · Source ↗
5 November 2026Priority reviewIvonescimabNMPA grants priority review to ivonescimab plus chemotherapy in first-line biliary tract cancer
CN, NMPA · Akeso · Source ↗
25 October 2026Topline resultIvonescimabPhase 3 HARMONi-GI1 met its primary endpoint of overall survival
12 August 2026ApprovalIvonescimabNMPA approves ivonescimab plus chemotherapy in first-line squamous NSCLC
CN, NMPA · Source ↗
29 January 2026Filing acceptedIvonescimabFDA accepts Summit's BLA for ivonescimab plus chemotherapy (EGFRm NSCLC post-TKI)
US, FDA · FDA · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$169M$151M+ $479M short-term inv.$208M-$160M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$158M$420M+ $271M short-term inv.$216M-$141M operating cash flowreport ↗
2026-Q1—$133M$107M+ $492M short-term inv.$189M-$122M operating cash flowreport ↗
2025-Q3——$239M+ $0 short-term inv.$232M-$93M operating cash flowreport ↗
2025-Q2—$208M$298M+ $0 short-term inv.$566M-$67M operating cash flowreport ↗
2025-Q1—$51M$212M+ $150M short-term inv.$63M-$61M operating cash flowreport ↗
2024-Q3$0—$94M+ $393M short-term inv.$56M-$30M operating cash flowreport ↗
2024-Q2——$29M+ $297M short-term inv.$60M-$33M operating cash flowreport ↗
2024-Q1—$31M$62M+ $95M short-term inv.$43M-$30M operating cash flowreport ↗
2023-Q3$0$15M$24M+ $175M short-term inv.$21M-$15M operating cash flowreport ↗
2023-Q2$0$9.4M$42M+ $173M short-term inv.$15M-$29M operating cash flowreport ↗
2023-Q1$0$9.9M$71M+ $171M short-term inv.$542M-$13M operating cash flowreport ↗
2022-Q3$0.2M$17M$122M$21M-$8.6M operating cash flowreport ↗
2022-Q2$0.2M$9.0M$57M$17M-$19M operating cash flowreport ↗
2022-Q1$0.3M$21M$77M$21M-$19M operating cash flowreport ↗
2021-Q3$1.3M$20M$80M$20M-$24M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY——$226M+ $488M short-term inv.$270M-$323M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0—$105M+ $307M short-term inv.$55M-$142M operating cash flowreport ↗
2023-FY$0$59M$71M+ $115M short-term inv.$154M-$77M operating cash flowreport ↗
2022-FY$0.7M$52M$649M+ $0 short-term inv.$20M-$42M operating cash flowreport ↗
2021-FY$1.8M$85M$72M$22M-$73M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 6 purchases ($103.6M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-16Soni Manmeet Singh · director, COO and CFOOption exercise100,000$1.37$137KForm 4
2026-11-16Zanganeh Mahkam · director, Co-Chief Executive Officer, 10% ownerOption exercise500,000$1.06$530KForm 4
2026-11-16DUGGAN ROBERT W · director, Co-Chief Executive Officer, 10% ownerOption exercise500,000$1.06$530KForm 4
2026-11-16Soni Manmeet Singh · director, COO and CFOOption exercise (derivative)100,000——Form 4
2026-11-16Zanganeh Mahkam · director, Co-Chief Executive Officer, 10% ownerOption exercise (derivative)500,000——Form 4
2026-11-16DUGGAN ROBERT W · director, Co-Chief Executive Officer, 10% ownerOption exercise (derivative)500,000——Form 4
2026-10-08Anand Bhaskar · Chief Accounting OfficerAward / grant100,000——Form 4
2026-06-12DUGGAN ROBERT W · director, Co-Chief Executive Officer, 10% ownerOpen-market purchase3,810,000$13.12$50.0MForm 4